



Wednesday

May 10, 2017

**Dermatology and
Dermatological
Surgery Society of
Connecticut**

**Annual Scientific
Educational Program**

**The Waterview
215 Roosevelt Drive
Monroe, Connecticut**

Education Mission Statement

We are committed to advancing the highest standards of skin care through continuing education activities. The Connecticut Dermatology and Dermatologic Surgery Society Semi-annual Scientific Education Programs are dedicated to improving and protecting our patient's skin health by presenting advances in the diagnosis and treatment of skin disease.

Our target audience includes dermatologists and their staff, including office managers and medical assistants. Activities range from didactic lectures to participatory activities, and whenever possible are approved for CME credit. We expect that our audience will incorporate best practices, as presented, into their daily practice. Specific competency, performance and patient outcome goals that will result from the program will be proposed by the presenters and evaluated by the participants.

(Reviewed 5/15/16
by the Executive Committee)

EXHIBITORS

Platinum

Genentech

Novartis Pharmaceuticals

Pfizer

Gold

AbbVie US, LLC

Amgen

Celgene Corp.

Cobalt Medical Supply, Inc.

CT Pharmacy Direct

Lilly USA, LLC

Sanofi/Regeneron

Silver

Actellion Pharmaceuticals

Bayer HealthCare

Beiersdorf, Inc.

Castle Biosciences, Inc.

Community Health Network of CT

Compounded Solutions in Pharmacy

Janssen Bio-Tech, Inc.

Mayne Pharma

Miraca Life Sciences

Mylan, Inc.

PruGen, Pharmaceuticals

Ra Medical

Strata Dx

Sun Dermatology

Taro Pharmaceuticals

3:00 **Registration - Vendor Expo**

3:30 **Tax Update: Ambulatory Surgery Centers and Cosmetic Tax**

– Lisa Winkler, Partner, Innovate & Organize; Bill Malitsky, Halloran and Sage

Objectives: 1. To identify various accounting methods for both surgery center tax and cosmetic tax. 2. To describe pass through tax methods medical offices can use to collect 6.35% tax from patients.

4:00 **MACRA, MIPS & APM: Positioning Your Practice for Success**

– Kelly Gilbert Raskauskas, MA

Objectives: 1. Provide an overview of the new MACRA Quality Payment Programs, MIPS and APM. 2. Outline MACRA participation options for 2017. 3. Discuss MIPS components, scoring, and reporting options.

4:45 **Welcome Reception with Wine Tasting in Exhibit Hall**

– **Come Meet the Residents and New Dermatologists in Connecticut**

5:15 **Update on Cosmetic Dermatology**

– Omar Ibrahim, MD, PhD

Objectives: 1. Understand new treatment options available with picosecond laser technology. 2. Understand the mechanism of action for novel body contouring techniques.

5:30 **Update on Medical Dermatology Therapeutics**

– Jeremy Moss, M.D.

Supported by an Independent Educational Grant from Novartis Pharmaceuticals Corporation

1.0 AMA PRA Category 1 Credit™ provided by AcademicCME

Objectives: 1. Understand the relative strengths and weakness of the new and pipeline therapies for atopic dermatitis. 2. Understand the role of the Th17 pathway in psoriasis especially as it relates to new therapies and therapies in development (IL-17 and IL-23 inhibitors).

6:00 Dinner with Vendors - Business Meeting

7:00 Melanoma immunotherapy: from Checkpoint to Checkmates

– Hensin Tsao, M.D.

Objectives: 1. Describe the currently available checkpoint inhibitors in melanoma and their clinical efficacy 2. Understand the determinants of response to these treatments

7:45 Dessert and Coffee in Exhibit Hall with Vendors

8:15 Treating Severe Alopecia Areata and Other Refractory Dermatoses: JAK Inhibitors, Something New for Dermatology

– Brett King, M.D.

Objectives: 1. Identify and describe a new class of medications that will be useful in dermatology. 2. Utilize JAK inhibitors for the treatment of severe alopecia areata and other refractory dermatoses. 3. Summarize the potential adverse effects of JAK inhibitors.

9:00 Interesting Cases from Across the State

– Moderator - Omar Ibrahim, MD, PhD

Objectives: To review challenging and interesting cases from members and discuss treatment options and optimal outcomes.

1) “A Mysterious Mamillated Mass”

– Sam Awan, MD

- 2) **“Basaloid Follicular Hamartoma Syndrome”**
– *Andrew Kelsey, MD*
- 3) **“A Hemorrhagic Eruption in Elderly Male”**
– *Claire Hamilton, MD*
- 4) **“A One Day Old with Multiple Ulcers”**
– *Nour Kibbie, MD*

9:15 **Certificates and Door Prizes**

This activity has been planned and implemented in accordance with the Essentials and Standards of the Connecticut State Medical Society through the joint sponsorship of CSEP and The Connecticut Dermatology & Dermatologic Surgery Society. CSEP is accredited by the CSMS to provide continuing medical education for physicians.

CSEP designates this educational activity for a maximum of 4.75 AMA PRA Category I Credit(s)[™] toward the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she spent in the activity.

Please note: No certificates will be handed out without completing and handing in the CME Evaluation Form suggested topics and speakers and outcome measurement questionnaire at the end of the program.

Thank you!

The Connecticut Dermatology and Dermatologic Surgery Society
P.O. Box 1079, 26 Sally Burr Road, Litchfield, CT 06759
Ph: 860-567-4911 Fax: 860-567-3591
debbieosborn36@yahoo.com
www.ctdermatologysociety.org

**Connecticut Dermatology Society
Financial Interest Disclosure Report May 10, 2017**

<i>Speaker</i>	<i>Financial Interest Received</i>
Sam Awan, MD	None
Claire Hamilton, MD	None
Omar Ibrahim, MD, PhD	Research funding/Discounted equipment: Lumenis Inc, Lutronic Inc. Syneron - Candela, Solta Medical, Zeltiq, Living Proof. Stockholder: Proctor & Gamble, Zeltiq, Kythera
Andrew Kelsey, MD	None
Nour Kibbie, MD	None
Brett King, MD	None
Jeremy Moss, MD	None
Kelly Gilbert Raskauskas, MA	None
Hensin Tsao, MD	None
Lisa Winkler	None

Financial disclosure forms available upon request.

SPEAKERS



OMAR IBRAHIMI, MD, PhD

Dr. Omar Ibrahim is the medical director of the Connecticut Skin Institute. He completed his Dermatology training at Harvard Medical School and a fellowship program in Mohs and Reconstructive Surgery, Laser and Cosmetic Surgery at the University of California – Davis. He is well known nationally having been an invited speaker at numerous national meetings, and written extensively about Mohs Surgery, Laser and Cosmetic Procedures. Dr. Ibrahim has published over 65 research articles and book chapters on skin cancer surgery, laser and cosmetic procedures in leading medical journals. He has also performed thousands of cases of Mohs Surgery and Laser and Cosmetic procedures. Dr. Ibrahim previously served as a Visiting Assistant Professor of Dermatology at Harvard Medical School in the Wellman Center for Photomedicine. The Wellman Center for Photomedicine is the world's leading research center where the majority of today's laser and cosmetic technologies were invented and tested. He is an active participant in many clinical trials of new technologies.



BRETT KING, MD

Dr. Brett King is Assistant Professor of Dermatology at Yale School of Medicine, specializing in skin diseases recalcitrant to first-line therapies, with a special interest in atopic dermatitis, alopecia areata, autoimmune bullous disease and morphea. He also conducts clinical trials to identify new treat-

ments for skin disorders. He sees patients at Yale Dermatology-Middlebury.



JEREMY MOSS, MD

Dr. Moss is in private practice in Bridgeport at Brookside Dermatology Associates. He received his MD PhD at NYU and then went to Yale for residency and fellowship. He specializes in medical and referral-based dermatology. Dr. Moss is a principal investigator for a number of FDA studies on new and emerging therapeutics for cutaneous diseases. He frequently lectures locally and nationally on a variety of dermatologic subjects. He has served on several different committees and boards for the American Academy of Dermatology and for the three different local hospitals he maintains affiliations with.



KELLY GILBERT RASKAUSKAS, MA

Kelly Gilbert Raskauskas is the Vice President of Communications for the Connecticut State Medical Society (CSMS). She also serves as the CSMS representative to the Connecticut Immunization Coalition and the Connecticut Department of Public Health Preparedness Advisory Committee. Prior to CSMS, Ms. Raskauskas oversaw member and provider communications for a multistate Medicaid managed care organization. She also worked as a communications consultant specializing in non-profits,

and served as press secretary for municipal, county and Congressional political campaigns.

Ms. Raskauskas holds a Master's degree in Public Policy from Harvard's Kennedy School of Government, and is a Fellow of the AHIP Academy for Healthcare Management (FAHM).



HENSIN TSAO, MD

Dr. Tsao is Professor of Dermatology at Harvard Medical School and serves as the Director of both the MGH Melanoma and Pigmented Lesion Center and the MGH Melanoma Genetics Program. He is also the Head of the Skin Cancer Genetics Laboratory in the Wellman Center for Photomedicine at MGH where he oversees a research program in melanoma genetics and therapeutics.

Dr. Tsao graduated Magna Cum Laude and Phi Beta Kappa from Brown University with a degree in Biochemistry and English. In 1993, he graduated Alpha Omega Alpha from the Columbia University College of Physicians and Surgeons with an MD degree and Columbia University Graduate School of Arts of Sciences with a PhD degree in Biophysics/Biochemistry. Dr. Tsao completed one year of clinical training in internal medicine and three years of dermatology residency, including a one-year Melanoma Fellowship, in the Harvard-affiliated hospitals. He concluded his training with a postdoctoral fellowship in the Division of Oncology at Massachusetts General Hos-

pital.

In 2001, Dr. Tsao joined the Wellman Center for Photomedicine and Department of Dermatology at MGH, where he established the Skin Cancer Genetics Laboratory and the MGH Melanoma Genetics Program in order to better understand the molecular basis of melanoma predisposition, progression and therapeutic response. He has been continuously funded for his research by various organizations including the National Institutes of Health, the American Skin Association, the Dermatology Foundation, the American Cancer Society, the Department of Defense and the Melanoma Research Alliance. In addition to his scientific program, in 2005, he became the Director of the MGH Melanoma and Pigmented Lesion Center, which is the oldest multidisciplinary melanoma unit in the country.

Dr. Tsao is the author of 200 peer-reviewed research articles, reviews, abstracts, textbook chapters and online media texts. He has also delivered over 250 presentations on melanoma, genetics and skin disease throughout the world including many keynote, plenary and named lectureships. He has received numerous awards including the Alfred Steiner Dean's Award and Titus Munson Coan Prize from Columbia University, the Deborah Shalita Marmour Clinical Career Development Award from the Dermatology Foundation, the Young Investigator Award, the Marion Sulzberger Award and a Presidential Citation Award from the American Academy of Dermatology (AAD), the D.M. Carter Award and the How-

ard Milstein Innovation Award from the American Skin Association, the William Montagna Award and Lectureship from the Society for Investigative Dermatology and the MGH Partners-in-Excellence Award for Leadership and Innovation and the MGH Cancer Center's "100" Award. For his clinical and scientific contributions, Dr. Tsao has been selected as one of Boston's Top Doctors in (2010-2016) and inducted into the American Dermatological Association and the American Society for Clinical Investigation in 2008 and 2009, respectively.

Dr. Tsao serves or has served on numerous committees in the American Academy of Dermatology. He is or has been the Chair of the AAD Melanoma/Skin Cancer Committee, Chair of the AAD Education Committee, Chair of the AAD Task Force on the ABCDE's of Melanoma and a Member of the Melanoma Guidelines Committee, AAD Council on Science and Research and Council on Communication. He was Chair of the Education Committee for the Society for Investigative Dermatology and a Member of the Melanoma/Skin Cancer Committee of the American Society for Clinical Oncology. Dr. Tsao is also one of Directors of the American Board of Dermatology. Dr. Tsao is on the Editorial Board of the British Journal of Dermatology, Journal of the American Academy of Dermatology, the Journal of Investigative Dermatology and the International Journal of Oncology and was the Editor-in-Chief for Journal Watch/Dermatology. He has served or continues to serve on study sections for the National Institutes of Health, the Dermatology Foundation, the American Cancer Society and Cancer UK. On a

grassroots level, he is on the Medical Advisory Board of the Melanoma Foundation of New England.

LISA WINKLER

Partner, Innovate & Organize; Bill Malitsky, Halloran and Sage

Pre-Competency Questions

Update on Cosmetic Dermatology

– Omar Ibrahimi, MD, PhD

Question 1. Which of the following treatment approaches is considered to be safer when using laser/energy based devices in skin of color?

- A) Using lasers with the smallest possible spot size
- B) Using lasers with the smallest possible pulse duration
- C) Using a laser between 670-800 nm wavelengths
- D) Using fractionated radiofrequency insulated microneedles
- E) Using a fractionated CO2 laser

Aplasia Cutis Congenita – Nour Kibbi, MD

Question 1. The morphology and distribution of the lesions of aplasia cutis congenita secondary to fetus papyraceus vary depending on:

- A. Maternal age at time of gestation
- B. Gestational age at the time of fetal reduction
- C. Number of monochorionic fetuses in a gestation
- D. Gestational age at the time of delivery
- E. The mother's HPV status

Question 2. Neonates with deep lesions of aplasia cutis congenita require monitoring because they are at risk for:

- A. Bone involvement
- B. Infection
- C. Joint contractures
- D. Healing with atrophic or hypertrophic scarring
- E. All the above

Treating Severe Alopecia Areata and Other Refractory Dermatoses: JAK Inhibitors, Something New for Dermatology – *Brett King, M.D.*

Question 1. What drug class shows promise for the treatment of severe alopecia areata? _____

Question 2. How do JAK inhibitors function to suppress disease? _____

Melanoma Immunotherapy: from Checkpoint to Checkmates – *Hensin Tsao, M.D.*

Question 1. Which of the following is the target of nivolumab?

- a. CTLA4
- b. BRAF
- c. MEK
- d. PD-1
- e. PD-L1

Question 2. Which is the most common side effect of anti-PD1 blockade?

- a. Colitis
- b. Pruritus
- c. Squamous cell carcinoma
- d. Secondary lymphoma
- e. Myocarditis

DISCLOSURE POLICY

Connecticut Dermatology and Dermatologic Surgery Society (CDDSS) in joint sponsorship with CSEP adheres to all ACCME Essential Areas, Standards, and Policies. It is CDDSS policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that CDDSS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

ACGME COMPETENCIES

This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies:

- Patient care
- Medical knowledge
- Practice-based learning and improvement
Interpersonal and communication skills

Physicians Survey Form

Dear Member,

In an effort to establish procedures for identifying and analyzing the continuing medical educational needs and interests of our members, we ask that you take a moment to fill out this form and objectively identify potential speakers and educational topics that you are interested in having at the Connecticut Dermatology & Dermatologic Surgery Society (CDDSS) Semi-Annual Educational Meetings.

CDDSS will try to accommodate requests in an expeditious manner and communicate the purpose or objectives for each CME activity to our membership. Furthermore, the CDDSS shall design and implement educational activities consistent in content and method with the stated objectives and with applicable CME standards. Upon completion of each educational activity CDDSS will evaluate the effectiveness of its CME activities in meeting identified educational needs and objectives.

If you have any questions or comments regarding CME activities, please contact Debbie Osborn at 860-459-4377, by mail: PO Box 1079, Litchfield, CT 06759 or by email at *debbieosborn36@yahoo.com*

Name: _____

Suggested Topics _____

Education Gap _____

Suggested Speakers _____

Notes:

SAVE THE DATE



**Semi -Annual
Scientific Educational
Program**

**Wednesday
October 25, 2017**

at

**The Aqua Turf Club
556 Mulberry Street
Plantsville, Connecticut**